33results about How to "Antitumor effect" patented technology

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF12, fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF121 fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.

Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

The present invention relates to integrin ligand modified long circulation liposome carrying anticarcinogen for injection, and is especially one kind of injected anticarcinogen carrying targeting liposome administration system. The efficient administration system is obtained through modifying the surface of liposome simultaneously with both polyethylene glycol and integrin containing arginine-glycine-asparagic acid sequence or RGD analogue.

Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity.

The present invention relates to compositions and methods for treating cancer, by administering a combination comprising a jasmonate derivative (e.g., methyl jasmonate or a compound of any of formulae I through VII or any of the jasmonate derivatives exemplified by such formulae) and at least one other agent selected from a chemotherapeutic agent (e.g., a nitroso-urea, a platinum compound, a taxane derivative, an antitumor antibiotic) and an inhibitor of glycolysis (e.g., 2-deoxy-D-glucose). The jasmonate derivative and the at least one other agent together provide a therapeutic effect, which is preferably synergistic (cooperative).

Provided is an antitumor agent targeting SIRPα, which inhibits binding between CD47 and SIRPα, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRPα. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRPα protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect. Further, the antitumor agent can effectively exhibit an antitumor action not only on cancer cells expressing SIRPα on a cell surface but also on cancer cells not expressing the SIRPα when used in combination with, for example, an immune checkpoint inhibitor and / or an antibody drug that specifically reacts with a cancer antigen and has ADCC and ADCP activities.

The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide.

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

The present invention provides for the use of a dimeric phthalide compound, the dimeric phthalide compound has broad anti-tumor activity, can directly inhibit the proliferation of tumor cells and induce cell death, but also indirectly inhibit the development of tumors by suppressing neovascularization. And further, the dimeric phthalide compound can be used alone or in combination to treat cancer, as well as in combination with chemotherapeutics to increase the efficacy of chemotherapeutics and decrease the toxicity of chemotherapeutics.

The invention relates to the field of novel 23-hydroxybetulinic acid fluorescent derivative organic synthesis and pharmaceutical chemistry and concretely relates to a 23-hydroxybetulinic acid fluorescent probe obtained through connection of a coumarin fluorophore to a 23-hydroxybetulinic acid skeleton. The invention discloses a use of the 23-hydroxybetulinic acid fluorescent derivative in antineoplastic mechanism research and a potential use of the 23-hydroxybetulinic acid fluorescent derivative in cancer treatment and especially relates to a use of the 23-hydroxybetulinic acid fluorescent probe in detection of target cell localization and uptake under action of 23-hydroxybetulinic acid.

The present invention provides a polysubstituted pyridine compound of Formula I, a preparation method, a use and a pharmaceutical composition thereof. The polysubstituted pyridine compound of Formula I according to the present invention has an excellent anti-tumor effect, can inhibit various cell kinases simultaneously, has significantly excellent pharmacokinetic characteristics, and is very suitable for oral and intravenous administration. The pharmaceutical composition according to the present invention can be useful for treating tumors and cancers.

The present invention relates to an oncolytic virus encoding a cytidine deaminase (CDAse) polypeptide, a composition comprising it, as well as their use for prophylactic or therapeutic purposes, and more particularly for the treatment of cancer. The present invention also provides a method for treating a disease or a pathologic condition comprising the administration of such an oncolytic virus or composition thereof and a process for preparing such an oncolytic virus.

The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of pro-angiogenic growth factor(s) and an MMP inhibitor, such pharmaceutical composition allowing for the enhanced therapy and / or prevention of neoplastic diseases and disorders.

The present invention relates to combination therapy for cancer with a WT1 peptide vaccine and temozolomide.

The invention relates to benzo-[k,l]thiaxanthene-3,4-dimethyl anhydride derivative-uridine conjugates, and a preparation method and application thereof. According to the invention, benzo-[k,l]thiaxanthene-3,4-dicarboamide parent ring having the properties of a DNA intercalator is conjugated with uridine having important biological activity to construct 3 novel target compounds. The above 3 target compounds are applied to research on the selective combining capacity of the promoter activation DNA sequence of the proto-oncogene c-myc highly expressed in some tumor cells at the extracellular molecule level; the above 3 target compounds are applied to research at the cell level, and research results show that all the three compounds have certain effects on killing two tumor cells, wherein compound 1 shows the strongest effect on killing the tumor cells; and the 3 compounds have substantial significance on the research and development of antitumor gene-targeted drugs having down-regulated c-myc gene and mediated by the benzo-[k,l]thiaxanthene-3,4-dimethyl anhydride derivative-uridine conjugates.

The present invention provides for the use of a dimeric phthalide compound, the dimeric phthalide compound has broad anti-tumor activity, can directly inhibit the proliferation of tumor cells and induce cell death, but also indirectly inhibit the development of tumors by suppressing neovascularization. And further, the dimeric phthalide compound can be used alone or in combination to treat cancer, as well as in combination with chemotherapeutics to increase the efficacy of chemotherapeutics and decrease the toxicity of chemotherapeutics.

A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen,R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells HCE 8693, human stomach cancer BGC-803 cells, human esophagus cancer CaEs-17 cells, human breast cancer cells MCF-7, human ovarian cancer cells A2780, pancreatic cancer cells PC-3, human bladder cells EJ, human brain glia cells TG-905, human leukemia cells K562, human melanoma M 14 cells and human anaplastic thyroid carcinoma TA-K cells. They can be used to prepare anti-tumor medicament and have significant clinic value.

The disclosure relates to compositions and methods for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Use of gemcitabine, including in self-emulsifying orally administered dosage forms for these purposes is described. Gemcitabine is orally administered in a metronomic manner, which involves repeatedly administering a therapeutic amount of gemcitabine, being a fraction of the maximum tolerated dose, over an extended period of time, preferably on a non-interrupted schedule of weeks, months, or indefinitely.

A halogenated dideoxy sugar derivative, having the following general structure I wherein X is halogen,R1 and R2 are H or Br; R3 and R4 are OH or OAc. The compounds 1-14 of the current invention has strong inhibition effect on human nasopharyngeal cancer CNE-2Z cells, human lung cancer A549 cells. human colon cancer HT-29 cells, human liver cancer Bel-7402 cells, human rectum cancer cells HCE 8693, human stomach cancer BGC-803 cells, human esophagus cancer CaEs-17 cells, human breast cancer cells MCF-7, human ovarian cancer cells A2780, pancreatic cancer cells PC-3, human bladder cells EJ, human brain glia cells TG-905, human leukemia cells K562, human melanoma M 14 cells and human anaplastic thyroid carcinoma TA-K cells. They can be used to prepare anti-tumor medicament and have significant clinic value.

The invention relates to a preparation method of a magnolia zenii bark extract. The preparation method includes the following steps: drying magnolia zenii barks to the moisture content of less than 10%, soaking with 8 times the amount of a 95% industrial alcohol for 3 times at the room temperature, wherein in the first time, soaking for 2-4 months, in the second time, soaking for 1-2 months, and in the third time, soaking for 20-40 days; and merging the three leached solutions, carrying out reduced pressure concentration, and thus obtaining the magnolia zenii bark extract. The magnolia zenii bark extract can be used as an effective ingredient for preparing anti-cancer drugs. The preparation method has simple and reasonable design, and can effectively extract to obtain effective ingredients of the magnolia zenii root bark; and the obtained extract has a better anti-tumor effect.

The present invention relates to the technical field of medicine, which provides a liposomal docetaxel palmitate formulation and a method for preparing the said formulation. The liposomal docetaxel palmitate formulation contains docetaxel palmitate as the main drug, a chelating agent, lecithin and DSPE-PEG2000. It is characterized in that docetaxel is prepared into a docetaxel palmitate lipophilic prodrug, thus overcoming the defect that docetaxel cannot be processed into liposomes due to poor hydrophilicity and hydrophobicity. The liposome prescription of this invention contains a chelating agent with a substantive effect that can prolong the action time of the drug in the body, improve the anti-tumor effect and be prepared smoothly. Therefore, the chelating agent in the formulation is the core technical feature of the present invention. The purpose of the present invention is to develop a more efficient docetaxel palmitate liposome with no solubilizer so that it can be prepared more easily

The invention belongs to the biology technical field, relating an antineoplastic agent taking IL-23 gene or a cell introduced to the IL-23 gene as effective ingredient. The invention comprises the antineoplastic agent taking the following substances as the effective ingredient: a virus representing the IL-23 gene or non-virus carrier, a tumor cell introduced the IL-23 gene losing fission ability and an immune cell introduced the IL-23 gene. The antineolastic agent of the invention can be used independently or be combined with the treatment methods of operation, actinotheraphy and medical treatment for improving the cell immune response of organism, thereby achieving the aim of decreasing tumor volume, preventing transfer and preventing the recurrence of the tumor.

The invention discloses application of a thiourea molecule in preparation of antitumor drugs. The structural formula of the thiourea molecule is selected from formula I to formula IV, wherein R1, R2 and R3 are independently selected from hydrogen, alkyl with a carbon number of 1-10, aryl or a heteroatom group containing N, O and S. The invention provides new application of the thiourea molecule, specifically in preparation of anticancer drugs. The thiourea molecule is adopted as the anti-cancer drug, or is used as the active ingredient for preparation of pharmaceutical preparations, the antitumor drugs show very low cytotoxicity to human lung adenocarcinoma cells (A549), human breast cancer cells (BCap-37), human oral epidermoid carcinoma cells (KB), human lung fibroblast (HFL1) and human bronchial epithelial cells (BEAS-2B), but has very good antitumor effect at the animal level. (formula I, formula II, formula III, and formula IV).

The invention relates to benzo-[k,l]thiaxanthene-3,4-dimethyl anhydride derivative-uridine conjugates, and a preparation method and application thereof. According to the invention, benzo-[k,l]thiaxanthene-3,4-dicarboamide parent ring having the properties of a DNA intercalator is conjugated with uridine having important biological activity to construct 3 novel target compounds. The above 3 target compounds are applied to research on the selective combining capacity of the promoter activation DNA sequence of the proto-oncogene c-myc highly expressed in some tumor cells at the extracellular molecule level; the above 3 target compounds are applied to research at the cell level, and research results show that all the three compounds have certain effects on killing two tumor cells, wherein compound 1 shows the strongest effect on killing the tumor cells; and the 3 compounds have substantial significance on the research and development of antitumor gene-targeted drugs having down-regulated c-myc gene and mediated by the benzo-[k,l]thiaxanthene-3,4-dimethyl anhydride derivative-uridine conjugates.

The present invention relates to integrin ligand modified long circulation liposome carrying anticarcinogen for injection, and is especially one kind of injected anticarcinogen carrying targeting liposome administration system. The efficient administration system is obtained through modifying the surface of liposome simultaneously with both polyethylene glycol and integrin containing arginine-glycine-asparagic acid sequence or RGD analogue.

A cell preparation for treating brain tumors used in combination with a prodrug that is converted to 5-fluorouracil by cytosine deaminase, wherein the cell preparation comprises neural stem cells derived from pluripotent stem cells having a cytosine deaminase gene and a uracil phosphoribosyltransferase gene is provided to establish new means for treating brain tumors.

The invention belongs to the biology technical field, relating an antineoplastic agent taking IL-23 gene or a cell introduced to the IL-23 gene as effective ingredient. The invention comprises the antineoplastic agent taking the following substances as the effective ingredient: a virus representing the IL-23 gene or non-virus carrier, a tumor cell introduced the IL-23 gene losing fission ability and an immune cell introduced the IL-23 gene. The antineolastic agent of the invention can be used independently or be combined with the treatment methods of operation, actinotheraphy and medical treatment for improving the cell immune response of organism, thereby achieving the aim of decreasing tumor volume, preventing transfer and preventing the recurrence of the tumor.

Provided is an antitumor agent targeting SIRPα, which inhibits binding between CD47 and SIRPα, the antitumor agent being more effective. The present invention also provides an antitumor agent capable of more effectively exhibiting an antitumor effect when used in combination with an immune checkpoint inhibitor or an antibody drug. The antitumor agent includes as an active ingredient a substance that molecularly targets an IgV domain, which is an extracellular domain of SIRPα. The antitumor agent of the present invention, including as an active ingredient a substance that molecularly targets an IgV domain of SIRPα protein, activates M1-type macrophages, which have cytotoxicity to cancer cells, and immunocompetent cells to provide an effective antitumor effect. Further, the antitumor agent can effectively exhibit an antitumor action not only on cancer cells expressing SIRPα on a cell surface but also on cancer cells not expressing the SIRPα when used in combination with, for example, an immune checkpoint inhibitor and / or an antibody drug that specifically reacts with a cancer antigen and has ADCC and ADCP activities.